| 1484 |
National Cancer Institute |
Html |
en |
Pituitary Tumors Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of pituitary tumors. |
| treatment | 0.39139 |
| diagnostic imaging choice | 0.347546 |
| magnetic resonance imaging | 0.340677 |
| pituitary tumors | 0.690926 |
| pituitary adenomas | 0.92392 |
| medical therapy exists. | 0.351515 |
| pituitary lesion | 0.527537 |
| transsphenoidal microsurgical approach | 0.343275 |
| visual field | 0.394767 |
| cell-type specific presentations | 0.354594 |
| medical therapy | 0.38784 |
| pituitary gland | 0.541344 |
| gonadotroph adenomas | 0.356536 |
| important clinical presentation | 0.355104 |
| pituitary carcinomas | 0.731658 |
| useful diagnostic tool | 0.338617 |
| inactive pituitary adenomas | 0.650057 |
| endocrine-inactive adenomas | 0.359468 |
| pituitary adenoma | 0.802139 |
| pituitary apoplexy | 0.612406 |
| hormone-producing adenomas | 0.35841 |
| Conventional radiation therapy | 0.361094 |
| functional criteria | 0.339781 |
| GH-receptor antagonists | 0.338498 |
|
| adjunctive radiation therapy | 0.355238 |
| MRI scan | 0.341418 |
| effective medical treatment | 0.350208 |
| pituitary disorders | 0.546502 |
| appropriately selected patients | 0.348512 |
| dopamine analogues | 0.357798 |
| pituitary tumor | 0.625147 |
| Sagittal T1-weighted images | 0.340975 |
| patients | 0.403665 |
| surgically high-risk patients | 0.358813 |
| adjunctive medical therapy | 0.353866 |
| Hormone-secreting pituitary carcinomas | 0.652967 |
| significant suprasellar extension | 0.453203 |
| safe surgical treatment | 0.370545 |
| gross total tumor | 0.361957 |
| surgical management | 0.338442 |
| pituitary adenoma literature | 0.647061 |
| pituitary neoplasms | 0.533177 |
| postoperative radiation therapy | 0.355824 |
| radiation therapy | 0.637553 |
| somatostatin analogues | 0.402133 |
| ergot-derived dopamine agonists | 0.339339 |
| pituitary tumors. | 0.521498 |
|
CLICK HERE |
| 1525 |
National Cancer Institute |
Html |
en |
Prostate Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of prostate cancer. |
| Gleason score | 0.479579 |
| stage II prostate | 0.274733 |
| prostate gland | 0.299389 |
| Digital rectal exam | 0.35449 |
| body | 0.293669 |
| advanced prostate cancer | 0.31933 |
| PDQ cancer information | 0.312303 |
| clinical trial search | 0.317203 |
| PSA level | 0.375326 |
| clinical trials | 0.630272 |
| metastatic prostate cancer | 0.326945 |
| cancer information summary | 0.293408 |
| clinical trial | 0.478353 |
| prostate cancer cells | 0.379555 |
| patients | 0.279925 |
| stage III prostate | 0.274165 |
| radiation therapy | 0.706978 |
| beam radiation therapy | 0.284995 |
| radioactive seeds | 0.279855 |
| Recurrent prostate cancer | 0.344704 |
| treatment | 0.475447 |
| prostate biopsy | 0.278369 |
| magnetic resonance imaging | 0.29143 |
| general information | 0.285325 |
| NCI-supported cancer | 0.281722 |
|
| cancer cells | 0.470422 |
| standard radiation therapy | 0.280665 |
| radical prostatectomy | 0.336986 |
| treatment clinical trials | 0.285008 |
| radioactive material | 0.277278 |
| National Cancer Institute | 0.336961 |
| Prostate Cancer Treatment | 0.329429 |
| high-intensity–focused ultrasound therapy | 0.287706 |
| hormone therapy | 0.461026 |
| benign prostatic hyperplasia | 0.328811 |
| new treatment | 0.295081 |
| external radiation therapy | 0.479863 |
| stage IV prostate | 0.27349 |
| prostate cancer | 0.898521 |
| cancer clinical trials | 0.332604 |
| prostate surgery | 0.277806 |
| prostate cancer surgery | 0.324678 |
| internal radiation therapy | 0.335143 |
| high PSA level | 0.327595 |
| cancer | 0.953437 |
| information | 0.335184 |
| standard treatment | 0.325661 |
| early-stage prostate cancer | 0.320186 |
| Transrectal ultrasound | 0.294546 |
|
CLICK HERE |
| 1680 |
National Cancer Institute |
Html |
en |
Levels of Evidence for Supportive and Palliative Care Studies (PDQ®)–Health Professional Version |
Information about how to weigh the strength of the evidence obtained in supportive and palliative care studies. |
| evidence | 0.729835 |
| randomized studies | 0.672467 |
| strength | 0.608575 |
| nonrandomized controlled trials | 0.595875 |
| strongest evidence practicable | 0.654865 |
| longitudinal study | 0.526045 |
| peer-reviewed biomedical literature | 0.587944 |
| cross-sectional studies | 0.531226 |
| PDQ cancer information | 0.758262 |
| care information summaries | 0.62193 |
| intervention group | 0.604369 |
| study allocation | 0.53314 |
| palliative care information | 0.823406 |
| small systematic errors | 0.570225 |
| cancer information summary | 0.701569 |
| breast cancer prevention | 0.573045 |
| individual studies | 0.601761 |
| longitudinal data collection | 0.577183 |
| intervention assignment | 0.523855 |
| clinical research studies | 0.633829 |
| study design | 0.615878 |
| NCI’s PDQ | 0.55952 |
| randomized trials | 0.663127 |
| NCI PDQ cancer | 0.644613 |
| nonconsecutive case series | 0.579194 |
|
| randomized clinical trials | 0.69518 |
| existing evidence | 0.561312 |
| prospective cohort studies | 0.650344 |
| path analytic approaches | 0.562167 |
| study | 0.665927 |
| intervention delivery | 0.524571 |
| case series | 0.750668 |
| consecutive case series | 0.582028 |
| PDQ health professional | 0.694282 |
| palliative care | 0.971465 |
| PDQ Supportive | 0.594927 |
| strongest evidence | 0.656252 |
| expert consensus opinion | 0.580453 |
| study interventions | 0.528496 |
| PDQ documents | 0.562286 |
| Palliative Care Editorial | 0.622454 |
| prospective cohort study | 0.650315 |
| study results | 0.53118 |
| well-designed descriptive studies | 0.623668 |
| best possible evidence | 0.648181 |
| confounding design issues | 0.613307 |
| palliative care decisions | 0.625851 |
| best available evidence | 0.645573 |
| previously conducted studies | 0.598366 |
|
CLICK HERE |
| 1916 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de endometrio (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de endometrio. |
| estadios iva | 0.30531 |
| siguientes procedimientos | 0.345561 |
| estadio iv | 0.416394 |
| ingle.ampliar cáncer | 0.337906 |
| pequeña cantidad | 0.305869 |
| estadios ia | 0.305529 |
| rayos x | 0.305673 |
| estadio ivb | 0.327117 |
| estadio ib | 0.346728 |
| estadio ia | 0.346007 |
| estadio iva | 0.326507 |
| National Cancer Institute | 0.304825 |
| ecografÃa transvaginal | 0.319572 |
| estadios iiia | 0.305999 |
| áreas anormales.ampliar examen | 0.309172 |
| Instituto Nacional | 0.308479 |
| PDQ Tratamiento | 0.328152 |
| estadio iiia | 0.327997 |
|
| estadio iiic | 0.32708 |
| ecograma.ampliar ecografÃa | 0.306359 |
| Physician Data Query | 0.317231 |
| proteÃna llamada mTOR | 0.307532 |
| último panel | 0.306492 |
| estadio iii | 0.451856 |
| pequeña incisión | 0.304896 |
| cuello uterino | 0.921387 |
| salpingooforectomÃa bilateral | 0.354579 |
| revestimiento endometrial examen | 0.3113 |
| histerectomÃa abdominal | 0.308157 |
| cuerpo.ampliar cáncer | 0.338631 |
| útero).ampliar cáncer | 0.339682 |
| intestinos.ampliar cáncer | 0.338147 |
| útero.ampliar cáncer | 0.339136 |
| siguientes estadios | 0.306306 |
| baja densidad | 0.306437 |
|
CLICK HERE |
| 1950 |
National Cancer Institute |
Html |
es |
Tratamiento del linfoma primario del sistema nervioso central (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del linfoma primario del sistema nervioso central. |
| PDQ Tratamiento | 0.61533 |
| siguientes procedimientos | 0.603081 |
| células madre | 0.655295 |
| presente sección | 0.6017 |
| cerebro.ampliar quimioterapia | 0.604557 |
| sistema nervioso central | 0.993337 |
| Physician Data Query | 0.604007 |
| vÃa oral | 0.602155 |
| rayos x | 0.602876 |
|
| cáncer.Las pruebas | 0.604229 |
| cáncer.ampliar aspiración | 0.603004 |
| lÃquido cefalorraquÃdeo | 0.626647 |
| altas dosis | 0.60123 |
| National Cancer Institute | 0.600645 |
| siguientes riesgos | 0.60046 |
| siguientes pruebas | 0.60942 |
| Instituto Nacional | 0.601773 |
|
CLICK HERE |
| 1978 |
National Cancer Institute |
Html |
es |
Tratamiento del sarcoma de tejido blando infantil (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del sarcoma de tejido blando infantil |
| siguientes procedimientos | 0.572366 |
| adultos jóvenes | 0.618386 |
| PEComas benignos | 0.520421 |
| tumores tritones | 0.52849 |
| siguientes especialistas | 0.521466 |
| siguientes tipos | 0.697577 |
| liposarcoma mixoide | 0.659974 |
| sitios distantes | 0.525197 |
| ganglio linfático centinela | 0.713108 |
| rayos x | 0.524788 |
| enlace drugs approved | 0.52436 |
| niño ayuda | 0.523158 |
| niñez causa efectos | 0.52815 |
| fibroso maligno óseo | 0.548741 |
| efectos tardÃos | 0.640971 |
| gen adenomatous polyposis | 0.545842 |
| afección hereditaria llamada | 0.539118 |
| PDQ Efectos tardÃos | 0.532211 |
| tratamiento.Algunas veces | 0.521926 |
| IRMN).Ampliar Imágenes | 0.521592 |
| tejido blando.Tumores | 0.625304 |
|
| llamada neurofibromatosis tipo | 0.557887 |
| PDQ Tratamiento | 0.932402 |
| determinadas células | 0.547825 |
| neurofibromatosis tipo | 0.611708 |
| crecimiento indoloro | 0.528079 |
| Tumor tritón | 0.66813 |
| hemangioendotelioma epitelioide | 0.64346 |
| fibromatosis tipo desmoide | 0.801794 |
| nuevos tipos | 0.520813 |
| partes distantes | 0.574313 |
| Fibrosarcoma .Hay | 0.537541 |
| Soft Tissue Sarcoma | 0.580634 |
| siguientes situaciones | 0.519249 |
| gen smarcb1 | 0.579139 |
| gen retinoblastoma | 0.531925 |
| sarcoma epitelioide | 0.662899 |
| distinto aspecto | 0.525573 |
| mediana edad | 0.523915 |
| siguientes pruebas | 0.592677 |
| fibroso maligno | 0.621252 |
|
CLICK HERE |
| 2062 |
National Cancer Institute |
Html |
es |
Exámenes para detectar el cáncer colorrectal y los pólipos |
Hoja informativa que describe las ventajas y desventajas de varios exámenes selectivos de detección del cáncer colorrectal. |
| fecal usa anticuerpos | 0.492705 |
| screening flexible sigmoidoscopy | 0.428806 |
| colonography without | 0.411418 |
| alta sensibilidad | 0.434525 |
| Screening colonoscopy | 0.418332 |
| colorectal-cancer screening | 0.417889 |
| Circulating tumour markers | 0.417801 |
| Schoen RE | 0.427721 |
| randomized controlled trials | 0.418478 |
| historial médico | 0.412157 |
| rectal cancers | 0.41141 |
| define patients with | 0.416784 |
| personas morirán | 0.419825 |
| flexible sigmoidoscopy screening | 0.425333 |
| seguro médico | 0.427103 |
| Preventive Services Task | 0.418828 |
| digital rectal examination | 0.417389 |
| bario ayuda | 0.41421 |
| prueba adn-fit | 0.46424 |
| pequeñas cantidades | 0.431615 |
| prospective evaluation | 0.428506 |
| Internal Medicine | 0.490577 |
| materia fecal usa | 0.61279 |
| Estados Unidos | 0.627755 |
| PubMed Abstract | 0.909181 |
|
| única prueba | 0.462783 |
| fecal occult blood | 0.543844 |
| sangre llamada | 0.43281 |
| versus fecal occult | 0.484081 |
| Noninvasive testing | 0.410836 |
| computed tomographic colonography | 0.451989 |
| principales factores | 0.410616 |
| prospective multicenter study | 0.41765 |
| regular —por ejemplo | 0.423251 |
| General Internal Medicine | 0.422201 |
| Servicios Preventivos | 0.435789 |
| controlled trial | 0.42874 |
| PLoS Medicine | 0.414525 |
| methylated sept9 | 0.411171 |
| riesgo promedio | 0.720816 |
| fecal immunochemical testing | 0.480317 |
| Affairs Cooperative Study | 0.41697 |
| computadora ensambla | 0.410696 |
| llamada dcbe | 0.410601 |
| llamada fit | 0.414186 |
| pequeño riesgo | 0.422784 |
| cuáles pruebas | 0.470698 |
| necesarios procedimientos | 0.459521 |
| New England Journal | 0.448594 |
|
CLICK HERE |
| 3577 |
National Cancer Institute |
Html |
en |
Apply for a Grant |
The NCI Grants Process provides an overview of the end-to-end lifecycle of grant funding. Learn about the types of funding available and the basics for application, review, award, and on-going administration within the NCI. |
| additional history | 0.334336 |
| funding | 0.219323 |
| primary roles | 0.363807 |
| American public | 0.328291 |
|
| cancer research discoveries | 0.582458 |
| NCI grants process | 0.956659 |
| scientific research projects | 0.504965 |
|
CLICK HERE |
| 16863 |
National Cancer Institute |
Html |
es |
Selected Vegetables y Sun's Soup (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso de Selected Vegetables y Sun's Soup como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| Centro Nacional | 0.402144 |
| pequeño número | 0.40122 |
| estadio iv | 0.404103 |
| New Hampshire Avenue | 0.401505 |
| Drug Administration | 0.400937 |
| Sun’s Soup | 0.535838 |
| NCI Best Case | 0.4027 |
| Sun's Soup | 0.648887 |
| Selected Vegetables | 0.997532 |
| mezcla original hongos | 0.402938 |
| fitoquÃmicos anticancerÃgenos | 0.401555 |
| Freeze-dried Selected Vegetables | 0.409927 |
| datos bibliográficos pubmed | 0.401627 |
| siguientes ingredientes | 0.401955 |
| siguientes preguntas | 0.400938 |
| cuerpo usa | 0.401378 |
| Dátil rojo | 0.401496 |
| siguientes riesgos | 0.401219 |
| Scutellaria barbata | 0.401858 |
|
| Instituto Nacional | 0.408304 |
| Salud Complementaria | 0.403343 |
| Visuals Online | 0.401103 |
| siguientes versiones | 0.401582 |
| complementarias revisa | 0.401573 |
| Physician Data Query | 0.406378 |
| personas enfermas | 0.401456 |
| Estados Unidos | 0.461182 |
| libre uso | 0.401151 |
| mezcla contenÃa hongos | 0.402782 |
| efectos secundarios dañinos | 0.402436 |
| página manejo | 0.401027 |
| ¿El tratamiento | 0.402145 |
| ¿Los beneficios | 0.40095 |
| juntos cam | 0.400907 |
| hierbas hedyotis | 0.40184 |
| Series Program | 0.400934 |
| medicina complementaria | 0.443276 |
|
CLICK HERE |
| 17231 |
National Cancer Institute |
Html |
es |
Secuenciación del ADN de tumores en el tratamiento de cáncer |
null |
| mutaciones impulsoras | 0.72633 |
| Investigación ClÃnica Proteómica | 0.72046 |
| MATCH Infantil | 0.761796 |
| máquina llamada secuenciador | 0.847349 |
| llamada secuenciación | 0.960353 |
|
| Darryl Leja | 0.794924 |
| gen egfr | 0.773791 |
| llamadas paneles | 0.73634 |
| mayorÃa surgen | 0.7646 |
|
CLICK HERE |